Back to results
US 11,230,596 B2Granted
Methods for treatment of cancer comprising TIGIT-binding agents
AssigneeMereo Biopharma 5, Inc.
InventorsJakob Dupont, Hema Parmar
Life of this patent
Estimating the term…
Abstract
Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
Claims13
A method of treating cancer in a human patient having cancer, comprising administering to said human patient a therapeutically effective amount of a full-length antibody that specifically binds the extracellular domain of human TIGIT,
- wherein the cancer comprises tumor-infiltrating lymphocytes (TILS) or regulatory T-cells;
- and
- wherein said full-length antibody that binds human TIGIT is capable of mediating antibody-dependent cell cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) and comprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).
Dependencies are inferred from the claim text.